Equities Analysts Set Expectations for Pharming Groups FY2025 Earnings - Defense World

PHARM Stock  EUR 0.83  0.02  2.35%   
About 61% of Pharming Group's investor base is looking to short. The analysis of current outlook of investing in Pharming Group NV suggests that many traders are alarmed regarding Pharming Group's prospects. The current market sentiment, together with Pharming Group's historical and current headlines, can help investors time the market. In addition, many technical investors use Pharming Group NV stock news signals to limit their universe of possible portfolio assets.
  
Equities Analysts Set Expectations for Pharming Groups FY2025 Earnings Defense World

Read at news.google.com
Google News at Macroaxis
  

Pharming Group Fundamental Analysis

We analyze Pharming Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Outstanding

Shares Outstanding Comparative Analysis

Pharming Group is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Pharming Group NV Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharming Group stock to make a market-neutral strategy. Peer analysis of Pharming Group could also be used in its relative valuation, which is a method of valuing Pharming Group by comparing valuation metrics with similar companies.

Complementary Tools for Pharming Stock analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Money Managers
Screen money managers from public funds and ETFs managed around the world
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years